- Conditions
- HIV-1 Infection
- Interventions
- Darunavir, Ritonavir, Tenofovir disoproxil fumarate, Emtricitabine, Placebo for Tenofovir disoproxil fumarate, Placebo for Maraviroc, Maraviroc
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 242
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pre-Exposure Prophylaxis of HIV Infection
- Interventions
- Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 253 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Chronic Hepatitis B
- Interventions
- standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
- Drug
- Lead sponsor
- Assembly Biosciences
- Industry
- Eligibility
- 18 Years to 71 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 17
- States / cities
- Beverly Hills, California • Coronado, California • Los Angeles, California + 10 more
- Conditions
- Human Immunodeficiency Virus
- Interventions
- emtricitabine/tenofovir disoproxil fumarate
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- HIV Infections, HIV-1, Human Immunodeficiency Virus Type 1
- Interventions
- TMC278, Efavirenz
- Drug
- Lead sponsor
- Tibotec Pharmaceuticals, Ireland
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 694 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more
- Conditions
- Chronic Hepatitis B
- Interventions
- Entecavir + Tenofovir, Adefovir + continuing Lamivudine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 1 more
- Conditions
- Infection, Human Immunodeficiency Virus, HIV Infections
- Interventions
- GSK1265744 10 mg, GSK1265744 30 mg, GSK1265744 60 mg, Efavirenz 600 mg, Rilpivirine 25 mg, Placebo, Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Dolutegravir 50 MG, Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet [DESCOVY]
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hepatitis B Virus (HBV)
- Interventions
- Tenofovir disoproxil fumarate (TDF), Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 3
- States / cities
- Oakland, California • Indianapolis, Indiana • Seattle, Washington
- Conditions
- Human Immunodeficiency Virus
- Interventions
- bictegravir/emtricitabine/tenofovir alafenamide
- Drug
- Lead sponsor
- Midland Research Group, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Oakland Park, Florida
- Conditions
- HIV Infections
- Interventions
- Kaletra + Isentress, Atripla
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 6
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 3 more
- Conditions
- HIV, Combination Therapy
- Interventions
- Atazanavir, Ritonavir (heat-stable), Raltegravir, Tenofovir/Emtricitabine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Palm Springs, California • San Francisco, California + 5 more
- Conditions
- HIV-1-infection
- Interventions
- B/F/TAF, F/TAF, DTG, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 66
- States / cities
- Phoenix, Arizona • Los Angeles, California • Oakland, California + 47 more
- Conditions
- Acute HIV Infection
- Interventions
- VRC07-523LS, PGT121.414.LS, Placebo, ART
- Biological · Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more
- Conditions
- HIV Infections
- Interventions
- blood draw
- Procedure
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 8 more
- Conditions
- HIV-1 Infection
- Interventions
- DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 599 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more
- Conditions
- Infection, Human Immunodeficiency Virus, HIV Infections
- Interventions
- Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 722 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more
- Conditions
- HIV-1-infection, Hepatitis B
- Interventions
- B/F/TAF
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Philadelphia, Pennsylvania
- Conditions
- Chronic Hepatitis B
- Interventions
- TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Jose, California • Detroit, Michigan + 1 more
- Conditions
- Hepatitis D, Chronic
- Interventions
- JNJ-73763989, Placebo, Entecavir (ETV) monohydrate, Tenofovir disoproxil, Tenofovir alafenamide (TAF)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 2
- States / cities
- Redwood City, California • Boston, Massachusetts
- Conditions
- HIV Infections
- Interventions
- Atazanavir, Didanosine (enteric-coated), Efavirenz, Emtricitabine, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine/Zidovudine
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,571 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 27
- States / cities
- Los Angeles, California • Torrance, California • Denver, Colorado + 16 more
- Conditions
- HIV Infection
- Interventions
- Elvitegravir, Raltegravir, EVG placebo, RAL placebo, Background regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 94
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Reyataz + Norvir + Truvada, Reyataz + Epzicom
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 44
- States / cities
- Hobson City, Alabama • Phoenix, Arizona • Bakersfield, California + 36 more
- Conditions
- HIV Infections
- Interventions
- Doravirine (DOR), Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF), Antiretroviral (ARV) medications
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Boston, Massachusetts • Memphis, Tennessee + 1 more